Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Belatacept (Primary) ; Efalizumab (Primary)
- Indications Islet cell transplant rejection
- Focus Therapeutic Use
- 08 Jun 2022 Results (between 2007 and 2009) evaluating a multimodal approach including islet and pancreas after islet (PAI) transplant utilizing CNI-free immunosuppression (IS) regimens, are presented at the 2022 American Transplant Congress.
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 03 Sep 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2017 as reported by ClinicalTrials.gov.